The new Agilent 1260 Infinity Hybrid SFC/UHPLC System packs two orthogonal separation modes into one instrument, bringing you more information from a single automated sequence.
Double your discovery
The new Agilent 1260 Infinity Hybrid SFC/UHPLC System packs two orthogonal separation modes into one instrument, bringing you more information from a single automated sequence. Switching between the two techniques SFC and UHPLC has never been so easy. A software-controlled valve allows you to alternate smoothly and reproducibly between SFC and UHPLC methods within a single analysis sequence – no hardware changes are needed and equilibration times are minimal.
The Agilent 1260 Infinity Hybrid SFC/UHPLC system is the only SFC system available that offers true UHPLC capability with a 600 bar power range. It also provides the broadest price/performance range of any SFC system available. Whether you want to upgrade your current Agilent 1100 or 1200 Series system, or start with the Agilent 1260 Infinity Analytical SFC system as a dedicated instrument, you can easily adapt your system to create a hybrid unit and then further expand your detection capabilities with an Agilent evaporative light scattering detector or a mass spectrometer from Agilent’s extensive LC/MS portfolio.
For more information please visit ref="https://ad.doubleclick.net/clk;251121170;75655683;e?http://www.agilent.com/chem/infinity-sfc">www.agilent.com/chem/infinity
A Dream Come True: Separation Science at Analytica
November 6th 2024At Analytica this year, an oral session titled “A Dream Comes True: Fantastic News from Analytical Chemistry” focused on cutting-edge techniques in separation science in Hall 5 of the International Congress Center Munich (ICM) International Congress Center Munich (ICM).
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.